Paul Gerard Guy Richardson
Dana-Farber Cancer Institute
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Multiple Myeloma Research and Treatments
Strong evidence · 4 supporting papers · latest 2026
Hematopoietic Stem Cell Transplantation
Strong evidence · 1 supporting paper · latest 2026
Hippo pathway signaling and YAP/TAZ
Strong evidence · 1 supporting paper · latest 2026
Economic and Financial Impacts of Cancer
Strong evidence · 1 supporting paper · latest 2026
COVID-19 Clinical Research Studies
Solid evidence · 1 supporting paper · latest 2026
Cancer Immunotherapy and Biomarkers
Solid evidence · 2 supporting papers · latest 2026
Myeloproliferative Neoplasms: Diagnosis and Treatment
Solid evidence · 2 supporting papers · latest 2026
Immune cells in cancer
Solid evidence · 1 supporting paper · latest 2026
Publications (10)
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
2026DOIPMID 42289183
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
2026DOIPMID 41951609
POSTER: MM-569: Mezigdomide, Carfilzomib, and Dexamethasone vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Results From the Phase 3 SUCCESSOR-2 Trial
2026DOI
Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)
2026DOI
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)
2026DOIPMID 41842719
Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers
2026DOIPMID 41741727
Observational survey of financial difficulties among patients with multiple myeloma and chronic lymphocytic leukaemia treated at US community oncology clinics (Alliance A231602CD)
2026DOI
Phase IIB , Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID ‐19
2026DOIPMID 42117493
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma
2026DOIPMID 42693161
MM-569: Mezigdomide, Carfilzomib, and Dexamethasone vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Results From the Phase 3 SUCCESSOR-2 Trial
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Dana-Farber Cancer Institute
Source: OpenAlex · retrieved 2026-09-29